Biogen - Largest Companies by Marketcap, Revenue, Net Income and Employees
Top Corporates Hub
Biogen
BIIB
|
NASDAQ
|
United States
865
-305
Rank
$32.85B
Market Cap
$9.67B
-$ 0.16B
-1.63%
Revenue
$1.90B
+$ 0.61B
+47.29%
Earnings
7.6K
+0K
+0.46%
Employees
About
Biogen, Inc. (BIIB)
Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA, ADUHELM for the treatment of Alzheimer's disease, and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.
- Sector: Health Technology
- Industry: Pharmaceuticals: Major
- Headquarters:
Latest News
-
Barclays Initiates Coverage On Biogen with Equal-Weight Rating, Announces Price Target of $185
20.02.2026 -
What Are Wall Street Analysts' Target Price for Biogen Stock?
16.02.2026 -
Biogen Pipeline Advances In Lupus And SMA Reshape Growth Outlook
10.02.2026 -
Why Biogen (BIIB) Is Up 8.2% After Mixed 2025 Earnings and Neurology Pipeline Updates – And What's Next
10.02.2026 -
Biologics License Application for Subcutaneous Formulation of “LEQEMBI®” (lecanemab) for the Treatment of Early Alzheimer’s Disease Designated for Priority Review in China
09.02.2026